की कीमत क्या है Corvus Pharmaceuticals, Inc. (CRVS)

का मूल्य Corvus Pharmaceuticals, Inc. (CRVS) है $14.07

का बाजार पूंजीकरण क्या है Corvus Pharmaceuticals, Inc. (CRVS)

का बाजार पूंजीकरण Corvus Pharmaceuticals, Inc. (CRVS) है $1.18B

Corvus Pharmaceuticals, Inc. (CRVS) P/S अनुपात

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

वर्ष	P/S अनुपात	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

P/S अनुपात

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	P/S अनुपात	P/S अनुपात में अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

कंपनी

P/S अनुपात

P/S अनुपात में अंतर

देश